Insider Transactions in Q4 2020 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2020
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,444
+6.93%
|
$28,888
$2.91 P/Share
|
|
Oct 06
2020
|
Elena Prokupets Director |
BUY
Conversion of derivative security
|
Indirect |
711,447
+50.0%
|
-
|
|
Oct 06
2020
|
Alain J Cohen Director |
BUY
Conversion of derivative security
|
Indirect |
4,203,757
+48.77%
|
-
|
|
Oct 06
2020
|
Malcolm Salter Director |
BUY
Open market or private purchase
|
Direct |
1,315
+7.6%
|
$24,985
$19.0 P/Share
|
|
Oct 06
2020
|
Malcolm Salter Director |
BUY
Conversion of derivative security
|
Direct |
14,679
+33.06%
|
-
|
|
Oct 06
2020
|
Bruce Downey Director |
BUY
Conversion of derivative security
|
Direct |
489,542
+42.01%
|
-
|
|
Oct 06
2020
|
Kenneth Carl Anderson Director |
BUY
Conversion of derivative security
|
Indirect |
134,406
+41.46%
|
-
|
|
Oct 06
2020
|
Kenneth Carl Anderson Director |
BUY
Conversion of derivative security
|
Direct |
18,040
+18.33%
|
-
|
|
Oct 06
2020
|
Marc A Cohen Director |
BUY
Open market or private purchase
|
Direct |
5,030
+50.0%
|
$95,570
$19.0 P/Share
|
|
Oct 06
2020
|
Marc A Cohen Director |
BUY
Conversion of derivative security
|
Indirect |
4,203,757
+44.5%
|
-
|
|
Oct 06
2020
|
William Mckee Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,263
+50.0%
|
$99,997
$19.0 P/Share
|